



# ABSTRACT CATEGORIES

The AACR Annual Meeting 2024 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2024. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is **November 16, 2023 (11:59 p.m. ET)** and the late-breaking and clinical trials abstract submission deadline is **January 8, 2024 (11:59 p.m. ET)**.

The abstract categories are listed in alphabetical order.

## BCS Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

### BCS01 Bioinformatics, Computational Biology, and Systems Biology (See also MCB08: Genomics)

- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Artificial intelligence and machine/deep learning
- Database resources
- Integrative computational approaches
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods
- Systems engineering
- Whole cell modeling
- Other

### BCS02 Convergent Science

- Artificial intelligence and machine/deep learning
- Digital pathology
- Early detection and imaging
- Integration of clinical and research data
- Integrative cancer science
- Liquid biopsy: Multi-analyte and multi-omic
- Mathematical modeling
- Network biology and precision medicine
- Physical sciences in oncology
- Other

## CH Chemistry

### CH01 Drug Discovery, Design, and Delivery

- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification and optimization
- Natural products
- Synthesis, metabolism, and disposition
- Targeted protein degradation
- Other

### CH02 Proteomics and Mass Spectrometry

- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

### CH03 Structural and Chemical Biology

- Chemical genetics and genomics
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other

## ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:  
**November 16, 2023 (11:59 p.m. ET)**  
Late-Breaking and Clinical Trials Abstract  
Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

### CL Clinical Research

(not including clinical trials, see also the Clinical Trials [CT] categories)

#### CL01 Biomarkers

Biomarkers predictive of therapeutic benefit  
Diagnostic biomarkers  
Early detection biomarkers  
Liquid biopsies: Circulating nucleic acids  
Liquid biopsies: Circulating tumor cells  
Metastasis biomarkers  
Prognostic biomarkers  
Spatial proteomics and transcriptomics  
Other

#### CL02 Biostatistics in Clinical Trials

Design and analysis of clinical trials  
New study designs: Theory, methodology, and modeling  
Statistical modeling for cancer studies  
Other

#### CL03 Clinical Endocrinology

(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)

Endocrine-related cancers  
Growth factors, receptors, and signal transduction  
Hormone receptors and diagnosis/prognosis  
Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors  
Neuroendocrine and other endocrine factors  
Nuclear receptors: Structure and function  
Preclinical studies of endocrine-related cancers  
Receptors and signal transduction  
Steroid hormone receptors  
Other

#### CL04 Clinical Research in the Elderly

Aging, immunity, and cancer  
Other

#### CL05 Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations

Biobanking/biospecimen collection  
Clinical trial design  
Community-engaged research/community-based participatory research  
Community outreach and patient accrual  
Other

#### CL06 Immuno-oncology

(See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)

Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other therapies including chemotherapy  
Immune mechanisms invoked by radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered antibodies  
Vaccines (oncolytic and prophylactic)  
Other

#### CL07 Pediatric Cancer – Clinical Investigations

(See also CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)

Adolescent and young adult oncology  
Childhood cancer drug development  
Immunotherapeutic approaches to pediatric cancer  
Pediatric cancer predisposition and surveillance  
Survivorship, late effects, and second cancers  
Therapeutic dosing, resistance, and combination therapy application  
Translational pediatric cancer research  
Other

#### CL08 Precision Oncology

Combination therapy  
Molecular targeted therapy  
Other

#### CL09 Radiation Oncology

(See TB07: Radiation Science; ET08: Preclinical Radiotherapeutics)  
Clinical radiotherapeutic studies  
Interventional radiology  
Modification of radiosensitivity  
Radiation therapy combinations  
Radiation-induced late effects/second cancers  
Radiation-induced resistance  
Other

#### CL10 Real-World Data and Real-World Evidence

Analyses using clinico-genomic databases  
Clinical informatics and data science  
Retrospective clinical analyses  
Other

#### CL11 Surgical Oncology (including Prophylactic Surgery)

Surgical intervention in early stage disease  
Surgical intervention in late stage disease  
Surgical outcomes after neoadjuvant therapy  
Surgical palliation for local control  
Surgical prophylaxis for high risk populations

#### CL12 Survivorship Research and Supportive Care

Biology of cell and tissue damage  
Cardio-oncology  
Comparative effectiveness research and cost-effective studies  
Late effects of cancer and its treatment, including second cancers  
Psycho-oncology  
Supportive care, palliation, and pain management  
Translational survivorship research  
Other

#### CL13 Translational Research – Molecular Biology in Clinical Oncology

(See also TB03: In Vivo Imaging and Anatomical and Molecular Pathology)  
Clinical imaging  
Cytogenetics and clinical molecular genetics  
Epigenetic therapy  
Functional and molecular imaging  
Molecular classification of tumors  
Radiomics  
Theranostics  
Tumor staging: Correlation of clinical and molecular markers  
Other

### CT Clinical Trials

#### CT01 Clinical Trials in Progress

Phase I clinical trials in progress  
Phase II clinical trials in progress  
Phase III clinical trials in progress

#### CT02 Phase 0 Clinical Trials

Phase 0 clinical trials

#### CT03 First-in-Human Phase I Clinical Trials

First-in-human phase I clinical trials

#### CT04 Phase I Adult Clinical Trials

(See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)  
Phase I adult clinical trials

#### CT05 Phase II Adult Clinical Trials

Phase II adult clinical trials

#### CT06 Phase III Adult Clinical Trials

Phase III adult clinical trials

#### CT07 Phase I, II, or III Clinical Trials in Pediatric Cancer

(See also CL07: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)  
Phase I clinical trials in pediatric cancer  
Phase II clinical trials in pediatric cancer  
Phase III clinical trials in pediatric cancer

# ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:  
**November 16, 2023 (11:59 p.m. ET)**  
Late-Breaking and Clinical Trials Abstract  
Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

## EN Endocrinology

**EN01 Molecular, Preclinical, and Clinical Endocrinology** (See also CL03: Clinical Endocrinology)  
Endocrine-related cancers  
Growth factors, receptors, and signal transduction  
Hormone receptors and diagnosis/prognosis  
Hormone signaling and inhibitors  
Hormone synthesis, metabolism, and inhibitors  
Neuroendocrine and other endocrine factors  
Nuclear receptors: Structure and function  
Preclinical studies of endocrine-related cancers  
Receptors and signal transduction  
Steroid hormone receptors  
Other

## ET Experimental and Molecular Therapeutics

**ET01 Biological Therapeutic Agents** (See also CL06: Immuno-oncology; IM01: Preclinical Immunotherapy)  
Antireceptors  
Apoptosis: Therapeutic manipulation  
Growth factor receptors and other surface antigens as targets for therapy  
Oncogenes, tumor suppressor genes, and gene products as targets for therapy  
Protein kinases and phosphatases as targets for therapy  
Role of microenvironment in therapeutic response  
Other

**ET02 Drug Discovery**  
Antibody technologies  
Biochemical modulators of the therapeutic index  
Combination chemotherapies  
Differentiation therapy  
New targets  
Novel assay technology  
Novel drug delivery systems  
Targeting the tumor microenvironment in drug development  
Other

**ET03 Drug Resistance**  
Drug resistance in molecular targeted therapies  
Drug transport and metabolism  
Novel mechanisms  
Regulation of gene expression in drug resistance  
Reversal of drug resistance  
Other

**ET04 Gene and Vector-Based Therapy**  
Antisense molecules  
Gene therapy and radiation studies  
Immune modulators  
Vector systems and targeting strategies  
Other

**ET05 Mechanisms of Drug Action**  
Cell cycle mechanisms of anticancer drug action  
Cellular responses to anticancer drugs  
Role of the microenvironment in therapeutic response  
Other

**ET06 Molecular Targets**  
Cell death pathways and treatment  
DNA damage and repair  
Identification of molecular targets  
Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes  
New nonclinical models for targets  
Other

**ET07 Pharmacology, Pharmacogenetics, and Pharmacogenomics** (See also CT04: Phase I Adult Clinical Trials)  
Cellular pharmacology  
Molecular pharmacology  
Pharmacogenetics and therapeutic response  
Pharmacogenomics  
Pharmacokinetics and pharmacodynamics  
Preclinical toxicology  
Other

**ET08 Preclinical Radiotherapeutics** (See also TB07: Radiation Science; CL09: Radiation Oncology)  
Interactions of new agents with radiation  
Modification of radiosensitivity  
Molecular targets of radiation response  
Normal tissue/cellular stress responses to radiation  
Radioprotectors and radiosensitizers  
Radiotherapeutic combinations  
Theranostics/radiotheranostics  
Other

**ET09 Small Molecule Therapeutic Agents**  
DNA-reactive agents  
Epigenetic targets  
HDAC and methyltransferase inhibitors  
Molecular glues  
Novel antitumor agents  
Novel targets and pathways  
PI3K/AKT inhibitors  
Platinum complexes  
Proteasome inhibitors  
Targeted protein degraders  
Topoisomerases  
Tubulin agents  
Tyrosine kinase and phosphatase inhibitors  
Other

## IM Immunology

**IM01 Preclinical Immunotherapy** (See also CL06: Immuno-oncology; ET01: Biological Therapeutic Agents)  
Adoptive cell therapy  
Combination immunotherapies  
Immune checkpoints  
Immune mechanisms invoked by other therapies including chemotherapy  
Immune mechanisms invoked by radiation therapy  
Immune monitoring/clinical correlates  
Immune response to therapies  
Immunomodulatory agents and interventions  
Inflammation, immunity, and cancer  
Modifiers of the tumor microenvironment  
Therapeutic antibodies, including engineered antibodies

Vaccines (oncolytic and prophylactic)  
Other

**IM02 Tumor Immunobiology**  
Adaptive immunity in tumors  
Epigenetic regulation of tumor immunity  
Inflammation and cancer: Metastasis  
Inflammation and cancer: Tumor initiation and progression  
Innate immunity to tumors  
Microbiome, inflammation, and cancer  
Novel animal models  
Oncogenic pathway-mediated regulation of inflammation and tumor immunity  
Tumor antigenicity/processing and presentation  
Tumor-induced immune suppression: Extrinsic factors  
Tumor-induced immune suppression: Intrinsic factors  
Other

## MCB Molecular/Cellular Biology and Genetics

**MCB01 Cell Cycle**  
CDKs and CDK inhibitors  
Cell cycle checkpoints  
Control of cell cycle progression  
Telomeres and telomerase  
Other

**MCB02 Cell Death**  
Apoptosis  
Autophagy  
Bcl-2 family proteins  
Caspases  
Effects on mitochondria/mitochondrial function  
Inhibitor of apoptosis (IAP) family proteins  
Necrosis and necroptosis  
Transcriptional control of apoptosis  
Other

## ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:  
**November 16, 2023 (11:59 p.m. ET)**  
 Late-Breaking and Clinical Trials Abstract  
 Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

### **MCB03 Cell Growth Signaling Pathways**

Cell signaling  
 Cell-cell interactions  
 Growth factors  
 GTPases, their regulators, and effectors  
 Kinases and phosphatases  
 Receptors  
 Tumor-stromal cell interactions  
 Ubiquitin and ubiquitin-like proteins  
 Other

### **MCB04 Cellular Stress Responses**

Hypoxia  
 Oxidative stress  
 Premature cellular aging  
 Senescence  
 Unfolded protein response  
 Other

### **MCB05 DNA Damage and Repair**

Chromosomal structural alterations/  
 translocations  
 Genomic instability  
 Homologous recombination  
 Mechanisms of genomic alterations  
 Radiation-induced DNA damage  
 Other

### **MCB06 Epigenetics and Epigenomics**

Chromatin structure and function  
 DNA methylation  
 Epigenetic changes as molecular  
 markers of cancer  
 Epigenomics  
 Gene silencing  
 Histone modification  
 Other

### **MCB07 Gene Regulation and Transcription Factors**

Chromatin structure and function  
 Gene expression  
 Mechanisms of transcription  
 Oncogenic transcription factors  
 Posttranscriptional and translational  
 control  
 Promoters and enhancers of  
 transcription  
 Protein-protein interactions in  
 transcription factor function  
 Regulation of transcription factor  
 function  
 Transcriptional control of cell  
 differentiation  
 Other

### **MCB08 Genomics** (See also BCS01: Bioinformatics, Computational Biology, and Systems Biology)

Functional genomics  
 Genomic profiling of tumors  
 High-throughput sequencing  
 Large-scale approaches to cancer gene  
 discovery  
 Microarrays  
 Other

### **MCB09 Metabolism and Cancer**

Metabolic pathways  
 Metabolomics  
 Mitochondrial function  
 Signaling pathways that regulate  
 metabolism  
 Other

### **MCB10 microRNAs and Other Noncoding RNAs**

Epigenetic control of miRNA expression  
 miRNA profiling in cancer  
 miRNA regulation of cancer biology  
 miRNA-based diagnostics  
 miRNA-based therapeutics  
 miRNAs as tumor suppressors/  
 oncogenes  
 Noncoding RNAs  
 Other

### **MCB11 Oncogenes and Tumor Suppressor Genes**

Cytoplasmic signal transducers  
 Genotype/phenotype correlations  
 Nuclear oncoproteins and tumor  
 suppressor genes  
 Oncogene growth factors and their  
 receptors  
 Tumor suppressor genes  
 Other

### **PS Population Sciences** (Including Diversity, Equity, and Inclusion)

#### **PS01 Population Sciences**

Aging as a risk factor  
 Biomarkers of endogenous or  
 exogenous exposures, early detection,  
 and biologic effects  
 Biomarkers of prognosis  
 Cancer disparities research  
 Descriptive epidemiology, covering  
 cancer incidence, mortality, clusters,  
 and trends  
 Diet, alcohol, tobacco use, and other  
 lifestyle risk factors  
 Environmental and occupational risk  
 factors  
 Familial and hereditary cancers  
 Functional studies of genetic variants  
 Gene-gene and gene-environment  
 interactions  
 Genome-wide association studies  
 (GWAS)/post-GWAS  
 Health services and comparative  
 effectiveness research  
 Implementation science  
 Infection and immune factors  
 Next-generation sequencing in  
 epidemiology studies (whole genome,  
 exome, targeted, or fine-mapping)  
 Pathway and candidate gene studies of  
 risk or prognosis  
 Pharmacoepidemiology  
 Preneoplastic and tumor markers  
 Primary and secondary intervention  
 studies  
 Psychosocial and behavioral  
 epidemiology  
 Risk prediction models for incidence,  
 prognosis, and/or mortality  
 Screening and early detection  
 Statistical and epidemiological  
 methodology  
 Survivorship research  
 Other

### **PR Prevention, Early Detection, and Interception** (Including Diversity, Equity, and Inclusion)

#### **PR01 Clinical Prevention, Early Detection, and Interception**

Application of molecular pathology in  
 clinical prevention  
 Biomarkers and intervention studies  
 Cancer disparities research  
 Cancer surveillance and screening  
 studies  
 Chemoprevention clinical trials  
 Genomics and proteomics in cancer risk  
 and response assessment  
 Infections and virus-related cancers  
 Microbiome and prevention  
 Obesity, diet, physical activity, and  
 energy balance  
 Prevention and treatment of  
 premalignant lesions (intraepithelial  
 neoplasia)  
 Prevention of second cancers  
 Quality of life/late effects/survivorship  
 Recruitment of racial and ethnic  
 minorities and other underserved  
 populations in clinical prevention trials  
 Screening and early detection  
 Other

#### **PR02 Preclinical Prevention, Early Detection, and Interception**

Animal models in prevention  
 Behavioral sciences and prevention  
 Biological and biochemical mechanisms  
 in prevention  
 Biomarkers and intervention studies  
 Cancer communication and decision  
 making  
 Cellular models  
 Chemoprevention studies  
 Diet, nutrition, and cancer  
 Microbiome and prevention  
 Molecular markers in prevention  
 research  
 Molecular targets for prevention  
 New agent development  
 Screening and early detection  
 Other

## ABSTRACT CATEGORIES *(cont'd)*

Regular Abstract Submission Deadline:  
**November 16, 2023 (11:59 p.m. ET)**  
 Late-Breaking and Clinical Trials Abstract  
 Submission Deadline: **January 8, 2024 (11:59 p.m. ET)**

### RSP Regulatory Science and Policy

#### RSP01 Regulatory Science and Policy

Biosimilars and generics  
 Clinical trial design and accrual  
 Combination therapies and codevelopment of investigational agents and diagnostics  
 Data science and informatics  
 International regulatory issues  
 Novel endpoints and biomarkers  
 Real-world evidence and retrospective analyses  
 Tobacco and e-cigarette regulation  
 Other

### SHP Science and Health Policy

#### SHP01 Science and Health Policy

Cancer disparities  
 Cancer survivorship  
 Implementation science  
 Patient advocacy and engagement  
 Value and cost issues in cancer care  
 Other

### TB Tumor Biology

#### TB01 Angiogenesis

Angiogenesis and angiogenesis inhibitors  
 Host-tumor interactions  
 Molecular mechanisms of angiogenesis  
 Novel pro- and antiangiogenic factors  
 Tumor microcirculation and the microenvironment  
 Other

#### TB02 Carcinogenesis

Chemical, environmental, and virus-induced carcinogenesis  
 Mutagenesis  
 Other

#### TB03 In Vivo Imaging and Anatomical and Molecular Pathology (See also CL13: Translational Research: Molecular Biology in Clinical Oncology)

Advanced nanotechnology and imaging  
 Application of imaging technology to the clinic  
 Imaging in animal models  
 Imaging of molecular and cellular events in the tumor microenvironment  
 Imaging of molecular and cellular events in tumors and tumor cells  
 Imaging the immune response  
 Imaging tumor metabolism  
 New targets for imaging  
 Other

#### TB04 Metastasis

Actin cytoskeleton  
 Biomarkers of metastasis  
 Epithelial/mesenchymal transition (EMT and MET)  
 Expression profiling of tumor progression and metastasis  
 Genes that regulate migration and invasion  
 Imaging of tumor progression and metastasis  
 Invasion and migration  
 Metastasis-promoting genes  
 Metastasis suppressor genes  
 Premetastatic niche  
 Therapeutic metastasis prevention  
 Other

#### TB05 Nonclinical Models of Cancer

3-D and tissue recombinant models  
 Developmental phenotypes of cancer genes  
 Human-in-mouse models of human cancer  
 Model organisms in drug discovery  
 Mouse models of human cancer  
 Noninvasive imaging in animal models  
 Organoids  
 Other animal and cell models of cancer  
 Patient-derived xenograft models  
 Zebrafish models of cancer  
 Other

#### TB06 Pediatric Cancer - Basic Science (See also CL07: Pediatric Cancer - Clinical Investigations; CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer)

Developmental origins and drivers of pediatric cancer  
 Pediatric cancer genomics and epigenomics  
 Pediatric cancer models  
 Pediatric cancer tumor microenvironment and tumor heterogeneity  
 Other

#### TB07 Radiation Science

(See also CL09: Radiation Oncology; ET08: Preclinical Radiotherapeutics)  
 Modulators of radiation response  
 Photobiology/photodynamic therapy  
 Radiation dose fractionation  
 Radiation-activated signaling pathways  
 Radiation-induced gene expression  
 Radiation-induced resistance  
 Radiobiology research  
 Radioprotectors and radiosensitizers  
 Other

#### TB08 Stem Cell Biology

Adult stem cells  
 Cancer stem cells  
 Developmental pathways in cancer  
 Embryonic stem cells  
 Stem cell markers  
 Stem cells and regenerative medicine in oncology  
 Other

#### TB09 Tumor Adhesion

Cell adhesion and extracellular matrix  
 Drug resistance  
 Other

#### TB10 Tumor Evolution and Heterogeneity

Causes and consequences of tumor heterogeneity  
 Clonal evolution  
 Methods to measure tumor evolution and heterogeneity  
 Other

#### TB11 Tumor Microenvironment

Chemokines in the microenvironment  
 Drug targets in the microenvironment  
 Extracellular matrix and integrins  
 Gene expression in the microenvironment  
 Immune cells in the tumor microenvironment  
 Inflammatory cells as regulators of tumor growth  
 Microbiome  
 Organ-specific microenvironments  
 Proteases and inhibitors in the microenvironment  
 Tumor dormancy  
 Tumor/stromal interactions  
 Tumor-immune system interactions  
 Other